Recent events
Recent events tied to this brand in public sources.
Back to profile61 entries · Page 1 of 4
2026
Sanofi reports third-quarter 2026 results
Sanofi reported third-quarter 2026 sales growth of 14.3% at constant exchange rates and business earnings per share of 3.55, up 19.6% at constant exchange rates from the third quarter of 2025.
2026
Sanofi raises 2026 full-year guidance
Sanofi raised its 2026 guidance, saying it now expects full-year sales to grow by a low-teens percentage and business earnings per share by a mid-teens percentage, both at constant exchange rates.
2026
Sanofi and Khalifa University genomic research agreement
Sanofi signed a genomic research agreement with Khalifa University to study genetic factors behind asthma and COPD using governed local health and genomic datasets. The article gives conflicting timing (“Last week” and “this week”), so the event date is set to the article’s publication date.
2026
Sanofi expands Regeneron partnership with deal worth up to $8 billion
Reuters reported that Sanofi expanded its partnership with Regeneron through a deal worth up to $8 billion, described as a win for Sanofi's new chief executive.
2022
Sanofi unveils a new corporate brand and logo
Sanofi revealed a new corporate brand and logo as part of its modernisation and transformation.
2022
FDA approves Sanofi's Enjaymo for cold agglutinin disease
The U.S. FDA approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusions due to hemolysis in adults with cold agglutinin disease. The source describes it as the first and only approved treatment for the condition.
2022
Sanofi unveils new corporate brand and logo
Sanofi unveiled a new corporate brand and logo, bringing its business units Sanofi Pasteur and Sanofi Genzyme, along with other acquired brands, under the singular Sanofi name and brand.
2022
ABL Bio and Sanofi announce Parkinson’s treatment collaboration
ABL Bio announced a collaboration and worldwide license agreement with Sanofi to develop and commercialize ABL301, a preclinical-stage treatment candidate for Parkinson’s disease and other potential indications. Sanofi is to receive worldwide exclusive development and commercialization rights once the transaction becomes effective.
2022
Sanofi and Exscientia announce drug-development partnership
Sanofi and Exscientia said they would partner to develop up to 15 drug candidates across oncology and immunology, in a deal worth up to $5.2 billion in milestone payments. Exscientia will lead discovery and design through candidate nomination, after which Sanofi will take charge of clinical development.
2021
Sanofi announces acquisition of Origimm
Sanofi announced the acquisition of Origimm Biotechnology, adding the company's ORI-001 acne vaccine candidate to Sanofi's early-stage pipeline. The article said the acquisition was expected to complete that month.
2021
Baidu and Sanofi sign LinearDesign licensing agreement
Baidu and Sanofi signed an agreement for Sanofi to integrate Baidu's LinearDesign mRNA sequence-design algorithm into its product design pipeline and use it to optimize mRNA design for research and development.
2021
Sanofi completes acquisition of Kadmon
Sanofi announced that it completed its acquisition of Kadmon Holdings, Inc.
2021
Sanofi completes acquisition of Translate Bio
Sanofi completed its acquisition of Translate Bio through a merger with a wholly owned Sanofi subsidiary. Translate Bio became an indirect, wholly owned subsidiary of Sanofi, and its shares were to cease trading on Nasdaq as of September 14, 2021.
2021
Sanofi announces acquisition of Kadmon
Sanofi announced its acquisition of Kadmon Holdings in a deal valued at $1.9 billion. The article says the purchase was intended to strengthen Sanofi's transplant business line.
2021
Virginia woman files Zantac cancer lawsuit
Deborah Haskins sued the makers of Zantac, alleging that the drug caused her esophageal cancer and that its makers failed to warn consumers of the risks. The article says research had not explicitly linked Zantac to cancer.
2021
FDA approves Nexviazyme for late-onset Pompe disease
The U.S. Food and Drug Administration approved Sanofi's Nexviazyme for treating patients aged one year and older with late-onset Pompe disease.
2021
Sanofi announces acquisition of Translate Bio
Sanofi said it would acquire U.S. mRNA technology developer Translate Bio for $3.2 billion.
2021
Sanofi becomes Paris 2024 Premium Partner
Sanofi and Paris 2024 announced that Sanofi will become a Premium Partner of the Paris 2024 Olympic and Paralympic Games. Sanofi said the commitment offered an opportunity to engage its employees in the sporting event.
2021
Sanofi announced as a premium partner of the Paris 2024 Olympic and Paralympic Games
Sanofi announced that it would become a Premium Partner of the Paris 2024 Olympic and Paralympic Games. The announcement was made on July 13, 2021.
2021
Sanofi partners with academic groups on amcenestrant trial
Sanofi said it partnered with academic cooperative groups to initiate a pivotal study of amcenestrant. Sanofi will sponsor and fund the global study and provide the investigational drug; the groups will conduct or oversee parts of the study.